Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Clasificación en acciones #25851
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Precio por acción
$15.31
Última sincronización: 2024-02-29
Capitalización bursátil
$45.70M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Icosavax, Inc. (ICVX)

Categoría

Historial del precio de la acción de Icosavax, Inc. (ICVX)
Precio más alto de cierre: $15.31 el 2024-02-01

Precio más bajo de cierre: $29.91 el 2021-07-01
Historial del precio de la acción de Icosavax, Inc. desde 2021 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2024 10.83%
2023 104.14%
2022 -70.48%
2021 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$539.14 36.71%
US
$1.04K 56.86%
NL
$120.74 -14.98%
AU
$761.87 7.04%
CH
$130.43 385.07%
US